Free Trial
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel
NASDAQ:CING

Cingulate Q1 2026 Earnings Report

Cingulate logo
$4.92 +0.45 (+10.07%)
As of 11:32 AM Eastern
ProfileEarnings HistoryForecast

Cingulate EPS Results

Actual EPS
-$0.95
Consensus EPS
-$0.53
Beat/Miss
Missed by -$0.42
One Year Ago EPS
N/A

Cingulate Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cingulate Announcement Details

Quarter
Q1 2026
Date
5/14/2026
Time
Before Market Opens
Conference Call Date
Thursday, May 14, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Cingulate's Q1 2026 Press ReleasePress Release
(8-K)
Cingulate's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Cingulate Earnings Headlines

Cingulate Reshapes Board Structure and Leadership Roles
May 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/cingulate-reshapes-board-structure-and-leadership-roles?utm_source=marketbeat.com&utm_medium=referral
CING: Building its cash position
May 19, 2026  |  msn.comhttps://www.msn.com/en-us/money/economy/cing-building-its-cash-position/ar-AA23zE3d
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
May 26 at 1:00 AM  |  Porter & Company (Ad)
Cingulate (NASDAQ:CING) Lowered to Strong Sell Rating by Wall Street Zen
May 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30780620
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294884/0/en/cingulate-inc-reports-first-quarter-2026-financial-results-and-provides-an-update-of-commercial-readiness-efforts-on-track-for-lead-adhd-asset-ctx-1301.html
10 Best NASDAQ Growth Stocks to Buy and Hold Forever
April 24, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/10-best-nasdaq-growth-stocks-to-buy-and-hold-forever-1743857/
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING), a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

View Cingulate Profile
Earnings Tools